12/25/2025

Janusmed kön och genus

Janusmed kön och genus – atezolizumab

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Atezolizumab

Atezolizumab

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.

  2. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.

  3. Pignot G, Barthélémy P, Borchiellini D. Sex Disparities in Bladder Cancer Diagnosis and Treatment. Cancers (Basel). 2024;16(23):.

  4. Tecentriq (atezolizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-16, cited 2025-12-14]

  5. Marchand M, Zhang R, Chan P, Quarmby V, Ballinger M, Sternheim N et al. Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemother Pharmacol. 2021;88(2):211-221.

  6. Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol. 2022;13:909027.

  7. Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J et al. Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023;149(11):9399-9408.

  8. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630.

  9. May P, Winter C, Hubrecht I, Ortner E, Strathmeyer S, Geyer R et al. Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer. Transl Lung Cancer Res. 2025;14(9):3836-3846.

  10. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.

  11. Shan W, Zhu J, Shen J. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. BMJ Open. 2025;15(6):e090087.

  1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H et al. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023;136(13):1583-1590.
  2. Lampimukhi M, Qassim T, Venu R, Pakhala N, Mylavarapu S, Perera T et al. A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma. Cureus. 2023;15(11):e49429.
  3. Pignot G, Barthélémy P, Borchiellini D. Sex Disparities in Bladder Cancer Diagnosis and Treatment. Cancers (Basel). 2024;16(23):.
  4. Tecentriq (atezolizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-10-16, cited 2025-12-14]
  5. Marchand M, Zhang R, Chan P, Quarmby V, Ballinger M, Sternheim N et al. Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemother Pharmacol. 2021;88(2):211-221.
  6. Liu W, Huo G, Chen P. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Front Immunol. 2022;13:909027.
  7. Schneidewind L, Kiss B, Zengerling F, Borkowetz A, Graf S, Kranz J et al. Gender-specific outcomes in immune checkpoint inhibitor therapy for advanced or metastatic urothelial cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023;149(11):9399-9408.
  8. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619-630.
  9. May P, Winter C, Hubrecht I, Ortner E, Strathmeyer S, Geyer R et al. Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer. Transl Lung Cancer Res. 2025;14(9):3836-3846.
  10. Mikami T, Liaw B, Asada M, Niimura T, Zamami Y, Green-LaRoche D et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database. J Neurooncol. 2021;152(1):135-144.
  11. Shan W, Zhu J, Shen J. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. BMJ Open. 2025;15(6):e090087.